Avalo Therapeutics Inc
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its nam… Read more
Avalo Therapeutics Inc (AVTX) - Total Liabilities
Latest total liabilities as of September 2025: $33.55 Million USD
Based on the latest financial reports, Avalo Therapeutics Inc (AVTX) has total liabilities worth $33.55 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Avalo Therapeutics Inc - Total Liabilities Trend (2012–2024)
This chart illustrates how Avalo Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Avalo Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Avalo Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Dasheng Times Cultural Investment Co Ltd
SHG:600892
|
China | CN¥477.97 Million |
|
Qinghaihuading Industrial Co Ltd
SHG:600243
|
China | CN¥348.55 Million |
|
SEACOR Marine Holdings Inc
NYSE:SMHI
|
USA | $414.83 Million |
|
Valuetronics Holdings Limited
F:GJ7
|
Germany | €756.88 Million |
|
Beijing North Star Company Limited
PINK:BEIJF
|
USA | $34.91 Billion |
|
Omai Gold Mines Corp
OTCQB:OMGGF
|
USA | $2.05 Million |
|
Wenzhou Yuanfei Pet Toy Products Co. Ltd. A
SHE:001222
|
China | CN¥227.19 Million |
|
Compugen
NASDAQ:CGEN
|
USA | $54.02 Million |
Liability Composition Analysis (2012–2024)
This chart breaks down Avalo Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.28 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.37 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Avalo Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Avalo Therapeutics Inc (2012–2024)
The table below shows the annual total liabilities of Avalo Therapeutics Inc from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $17.70 Million | +29.30% |
| 2023-12-31 | $13.69 Million | -69.09% |
| 2022-12-31 | $44.28 Million | -22.49% |
| 2021-12-31 | $57.13 Million | +197.67% |
| 2020-12-31 | $19.19 Million | +26.99% |
| 2019-12-31 | $15.11 Million | -69.37% |
| 2018-12-31 | $49.34 Million | +223.25% |
| 2017-12-31 | $15.26 Million | +174.44% |
| 2016-12-31 | $5.56 Million | -35.13% |
| 2015-12-31 | $8.57 Million | -77.81% |
| 2014-12-31 | $38.65 Million | +68.60% |
| 2013-12-31 | $22.92 Million | +1384.80% |
| 2012-12-31 | $1.54 Million | -- |